Home Biosimilar Antibodies Others Others Vopratelimab (Anti-ICOS / CD278)
For research use only. Not for use in humans.

Vopratelimab (Anti-ICOS / CD278)

Synonyms: ICOS， CD278

Vopratelimab (Anti-ICOS / CD278) is a humanized immunoglobulin G1-kappa agonist monoclonal antibody that binds specifically to the Inducible CO-Stimulator of T cells (ICOS). Vopratelimab exhibits antitumor immune response. MW: 145.5 KD.

Vopratelimab (Anti-ICOS / CD278)

Quality Control

Batch: A246301 Purity: 99% Protein concentration: 7.13mg/ml Endotoxin Level: ＜1EU/mg
99

Mechanism of Action

Description
Vopratelimab (Anti-ICOS / CD278) is a humanized immunoglobulin G1-kappa agonist monoclonal antibody that binds specifically to the Inducible CO-Stimulator of T cells (ICOS). Vopratelimab exhibits antitumor immune response. MW: 145.5 KD.

Product Details

CAS No.  2039148-04-2
Molecular Weight 145.5 kDa
Isotype Human IgG1
Source CHO
Purification AKTA
Sterility 0.2 μM filtered
Formulation 100 mM Pro-Ac, 20mM Arg, pH5.0
Storage
(From the date of receipt)		 Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT02520791 ACTIVE_NOT_RECRUITING Advanced Primary Cutaneous T-Cell Non-Hodgkin Lymphoma; Recurrent Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3a Follicular Lymphoma; Recurrent Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma; Recurrent Mycosis Fungoides; Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma; Refractory Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type; Refractory Grade 1 Follicular Lymphoma; Refractory Grade 2 Follicular Lymphoma; Refractory Grade 3a Follicular Lymphoma; Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma; Stage IB Mycosis Fungoides AJCC v7; Stage II Mycosis Fungoides AJCC v7; Stage III Cutaneous T-Cell Non-Hodgkin Lymphoma; Stage III Mycosis Fungoides AJCC v7; Stage IV Cutaneous T-Cell Non-Hodgkin Lymphoma; Stage IV Mycosis Fungoides AJCC v7 National Cancer Institute (NCI) 2016-09-13 PHASE1
NCT04549025 TERMINATED Drug: Pimivalimab|Drug: Vopratelimab NSCLC Jounce Therapeutics, Inc. 2020-10-19 PHASE2
NCT04319224 TERMINATED Drug: Vopratelimab|Drug: Ipilimumab|Drug: Nivolumab Cancer Jounce Therapeutics, Inc. 2020-03-10 PHASE1; PHASE2
NCT03989362 COMPLETED Drug: Vopratelimab|Drug: Ipilimumab Cancer Jounce Therapeutics, Inc. 2019-06-06 PHASE2

(data from https://clinicaltrials.gov, updated on 2026-06-26)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.